ÆüËÜÇÀ·Ý²½³Ø²ñ 2023ǯÅÙÂç²ñ¥×¥í¥°¥é¥à¸¡º÷

¥×¥í¥°¥é¥à½¸PDF ¿Ê¹ÔÃæ¤Î¥×¥í¥°¥é¥à°ìÍ÷
½ªÎ»¤·¤Þ¤·¤¿
Âç²ñ¥È¥Ã¥×¥Ú¡¼¥¸¤ËÌá¤ë
Âç²ñ¥×¥í¥°¥é¥à½¸¡¦Âç²ñ¹Ö±éÍ׻ݽ¸¡ÎPDF¡Ï¤ÎÊѹ¹ (¹¹¿·¡§4/19)
¿ä¾©¥Ö¥é¥¦¥¶¡§Chrome¡¢FireFox¡¢Edge¡¢Safari
(Internet Explorer¤Ç¤ÏÀµ¤·¤¯É½¼¨¤µ¤ì¤Ê¤¤¾ì¹ç¤¬¤¢¤ê¤Þ¤¹)
Recommended browsers: Chrome, FireFox, Edge, Safari
(May not display correctly in Internet Explorer)

»á̾:±ü¼±ÑÉ× ¤Î¸¡º÷·ë²Ì

1 - 2  / 2 <<< 1 >>>

1 - 2  / 2
<<< 1 >>>
1E06-09
2023/03/14 13:00
¥ß¡¼¥Æ¥£¥ó¥°¥ë¡¼¥à E
Reveromycin AÀ¸¹çÀ®¹ÚÁÇRevK-RevLÊ£¹çÂÎ¥â¥Ç¥ë¹½Â¤¤Ë´ð¤Å¤¯RevLÊÑ°Û¹ÚÁǤβòÀϤÈÁê¸ßºîÍÑÎΰè¤Î·èÄê
Analysis of RevL mutants based on model structure of RevK-RevL complex involved in reveromycin biosynthesis and determination of their interaction regions
¡û²¬Â¼ ±Ñ¼£1¡¢º´Æ£¡Ê¼®ùõ¡Ë ͵Èþ1¡¢±ü¼ ±ÑÉ×2¡¢·§ºä ¿ò2¡¢Ä¹ÅÄ ÍµÇ·1¡¢¹â¶¶ ½ÓÆó1
¡ûEiji OKAMURA1, Yumi SATO-SHIOZAKI1, Hideo OKUMURA2, Takashi KUMASAKA2, Hiroyuki OSADA1, TAKAHASHI Shunji1
1Íý¸¦CSRS¡¢2¹âµ±ÅÙ¸÷²Ê³Ø¸¦µæ¥»¥ó¥¿¡¼
1RIKEN CSRS, 2JASRI
1F04-03
2023/03/14 10:30
¥ß¡¼¥Æ¥£¥ó¥°¥ë¡¼¥à F
Furocoumarin·Ï²½¹çʪ£±¤ÎDHODHÆðÛŪÁ˳²µ¡¹½¤Î²òÌÀ
Inhibition mechanism of furocoumarin–type compound 1 toward DHODH
¡ûÃ渶 ¼Â¶ê1¡¢ÅÏîµ Àµ¸ç1¡¢º´Æ£ Æ»Âç1¡¢±ü¼ ±ÑÉ×2¡¢Àîë À¿3¡¢Ä¹ÅÄ ÍµÇ·1,3¡¢ÅÏÊÕ ¸­Æó1
¡ûMIKU NAKAHARA1, Shogo Watanabe1, Michio Sato1, Hideo Okumura2, Makoto Kawatani3, Hiroyuki Osada1,3, Kenji Watanabe1
1ÀŲ¬¸©ÂçÌô¡¢2JASRI¡¢3Íý¸¦´Ä¶­»ñ¸»¥»
1Dept. Pharm. Sci., Univ. Shizuoka, 2JASRI, 3RIKEN CSRS
1 - 2  / 2 <<< 1 >>>

1 - 2  / 2
<<< 1 >>>